Here is an answer for patents. Dr. Pestell ow
Post# of 154756
(Total Views: 629)
Posted On: 03/04/2019 8:03:20 PM
Re: Evil Rabbit #641
Here is an answer for patents.
Dr. Pestell owns and has good and, except as set forth on Schedule 5.9(b) , marketable title, free and clear of all Encumbrances, to all Intellectual Property Rights referenced under the heading “Seller Licensed Patents” on Schedule 4.1(a)(4) .
Schedule 4.1(a)(2)
CONTRACTS
Seller Agreements
•
Material Transfer Agreement, dated August 31, 2013, by and between Thomas Jefferson University and ProstaGene, LLC.
•
Intellectual Property Agreement, dated June 19, 2014, by and between Thomas Jefferson University and ProstaGene, LLC.
•
License Agreement, dated June 19, 2014, by and between Thomas Jefferson University and ProstaGene, LLC.
•
Patent License Agreement, dated January 11, 2016, by and between Richard Pestell, M.D. and ProstaGene, LLC.
•
The University of Texas Health Science Center at San Antonio Material Transfer Agreement, dated April 12, 2017, by and between The University of Texas Health Science Center at San Antonio and ProstaGene, LLC.
•
Master License Agreement, dated September 29, 2017 (effective date of January 1, 2017), by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Master Sponsored Research Agreement, dated September 29, 2017 (effective date of January 1, 2017), by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Research Plan #1 under the Master Sponsored Research Agreement, dated September 29, 2017, by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Intellectual Property Agreement, dated September 29, 2017 (effective date of January 1, 2017), by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Mutual Confidentiality Agreement, dated September 29, 2017 (effective date of January 1, 2017), by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Fee-for-Service Animal Research Agreement, dated January 1, 2018, by and between ProstaGene and CytoDyn Inc.
Supporting Documentation relating to Seller’s IP rights
•
Release Letter for 4 mouse prostate cancer cell lines derived from Primary Prostate Epithelial cells, they are generated by selective transduction with 4 distinct oncogenes (c-Myc, Ha-Ras, Neu, and c-Src), dated October 12, 2010, from Thomas Jefferson University to Dr. Richard Pestell and Dr. Xiaoming Ju.
•
Release Letter for Metastasis Inhibition by CCR5 Antagonists, dated May 7, 2012, from Thomas Jefferson University to Dr. Richard Pestell, Dr. Marco A. Velasco Velasquez and Dr. Xuanmao Jiao.
•
Inventor Waiver Request Decision Letter, dated January 10, 2014, from National Institutes of Health to Dr. Richard Pestell.
•
Release Letter for Gene Signatures Invention, dated June 16, 2014, from Thomas Jefferson University to Dr. Richard Pestell.
•
Inventor Waiver Request Decision Letter, dated May 12, 2015, from National Institutes of Health to Dr. Richard G. Pestell.
Also the pr,
Dr. Pestell owns and has good and, except as set forth on Schedule 5.9(b) , marketable title, free and clear of all Encumbrances, to all Intellectual Property Rights referenced under the heading “Seller Licensed Patents” on Schedule 4.1(a)(4) .
Schedule 4.1(a)(2)
CONTRACTS
Seller Agreements
•
Material Transfer Agreement, dated August 31, 2013, by and between Thomas Jefferson University and ProstaGene, LLC.
•
Intellectual Property Agreement, dated June 19, 2014, by and between Thomas Jefferson University and ProstaGene, LLC.
•
License Agreement, dated June 19, 2014, by and between Thomas Jefferson University and ProstaGene, LLC.
•
Patent License Agreement, dated January 11, 2016, by and between Richard Pestell, M.D. and ProstaGene, LLC.
•
The University of Texas Health Science Center at San Antonio Material Transfer Agreement, dated April 12, 2017, by and between The University of Texas Health Science Center at San Antonio and ProstaGene, LLC.
•
Master License Agreement, dated September 29, 2017 (effective date of January 1, 2017), by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Master Sponsored Research Agreement, dated September 29, 2017 (effective date of January 1, 2017), by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Research Plan #1 under the Master Sponsored Research Agreement, dated September 29, 2017, by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Intellectual Property Agreement, dated September 29, 2017 (effective date of January 1, 2017), by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Mutual Confidentiality Agreement, dated September 29, 2017 (effective date of January 1, 2017), by and between Baruch S. Blumberg Institute and ProstaGene, LLC.
•
Fee-for-Service Animal Research Agreement, dated January 1, 2018, by and between ProstaGene and CytoDyn Inc.
Supporting Documentation relating to Seller’s IP rights
•
Release Letter for 4 mouse prostate cancer cell lines derived from Primary Prostate Epithelial cells, they are generated by selective transduction with 4 distinct oncogenes (c-Myc, Ha-Ras, Neu, and c-Src), dated October 12, 2010, from Thomas Jefferson University to Dr. Richard Pestell and Dr. Xiaoming Ju.
•
Release Letter for Metastasis Inhibition by CCR5 Antagonists, dated May 7, 2012, from Thomas Jefferson University to Dr. Richard Pestell, Dr. Marco A. Velasco Velasquez and Dr. Xuanmao Jiao.
•
Inventor Waiver Request Decision Letter, dated January 10, 2014, from National Institutes of Health to Dr. Richard Pestell.
•
Release Letter for Gene Signatures Invention, dated June 16, 2014, from Thomas Jefferson University to Dr. Richard Pestell.
•
Inventor Waiver Request Decision Letter, dated May 12, 2015, from National Institutes of Health to Dr. Richard G. Pestell.
Also the pr,
Quote:
Under the terms of the definitive agreement, CytoDyn acquired substantially all of the assets of ProstaGene, including the transfer or assignment of certain intellectual property rights held by ProstaGene and Dr. Pestell.
(1)
(0)